This PubMed record reports a clinical trial titled “Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.” The article is published in Clinical Cancer Research and is identified as a Clinical Trial. The primary clinical focus is on first-line combination immunotherapy using nivolumab plus ipilimumab-based approaches in patients with metastatic non-small cell lung cancer (NSCLC).
The title indicates an analysis of “early detriment,” implying evaluation of early adverse outcomes or unfavorable early benefit–risk balance when using this first-line regimen. The PubMed landing page makes clear the trial nature and therapeutic context but does not include the trial’s methods, endpoints, or numerical outcomes in the supplied excerpt.
The article lists multiple authors from academic centers and industry. Lead and contributing authors include Hossein Borghaei and colleagues. Institutional affiliations span North America, Europe, and Asia, and include:
These affiliations reflect a multidisciplinary and multinational collaborative study team drawn from both academic medical centers and industry research groups.
Publication citation details shown on the PubMed record:
The PubMed page also displays a full-text link reference to Silverchair Information Systems and indicates that full text links are available. The DOI and PMID are provided for retrieval of the complete article from the publisher or library resources.
The PubMed record explicitly classifies this work as a Clinical Trial. Key clinical and pharmacologic keywords evident from the title and record include nivolumab, ipilimumab, first-line therapy, metastatic non-small cell lung cancer, and “early detriment analysis.” These terms define the topical scope of the study and are central to database indexing and search retrieval.
The PubMed excerpt provided here supplies bibliographic metadata, author and affiliation details, clinical trial designation, DOI, and PMID. It does not include the abstract text, trial design details, numerical results, safety or efficacy outcomes, statistical analyses, patient population characteristics, or authors’ conclusions. Specifics such as sample size, primary and secondary endpoints, timing and definition of “early detriment,” subgroup analyses, and any reported benefits or harms are not present in the supplied source content.
Because the supplied PubMed content is limited to metadata and page navigation elements, any clinical interpretation, summary of results, or recommendations cannot be derived from this source alone. The absence of the abstract and full-text content in the provided excerpt means that the actual findings and their clinical implications were not reported in the source material available for this rewrite.
To access the full study for complete methodological and outcome details, use the DOI (10.1158/1078-0432.CCR-25-0942) or the PubMed identifier (PMID 42360104) to retrieve the publisher PDF or the journal article on the Clinical Cancer Research website. The PubMed page references a Silverchair Information Systems full-text link. Readers seeking the trial’s design specifics, statistical analyses, reported early detriment metrics, and authors’ conclusions should consult the full text. Institutional or library access, or contact with the corresponding author or publisher, may be required for full access.
Summary note: This PubMed record documents a collaborative, multinational clinical trial assessing first-line nivolumab plus ipilimumab-based therapy in metastatic NSCLC and provides complete bibliographic identifiers and author affiliations. The supplied source excerpt does not report trial results, methods, or conclusions; those must be obtained from the full-text article referenced by the DOI/PMID.